laboratories
January 25, 2023 blogger analysis, analytics, AOAC, Business, Business Analysis, cannabis, CASP, compliance, develop, development, Dr, Dr. Katerina Mastovska, government, Growing, industry, International, Katerina, lab, laboratories, laboratory, legalization, Legalize, marijuana, Mastovska, Medicial Marijuana, method, Recreational, regulation, regulatory, safety, SMPR, standard, Standardization, Stop Smoking Marijuana, Stop Smoking Pot, weed, withdrawal
AOAC International, an independent nonprofit standards development organization has announced the appointment of Dr. Katerina (Kate) Mastovska as their new deputy executive director and chief science officer. Dr. Katerina Mastovska Most recently, Dr. Mastovska served as chief science officer for the Eurofins US Food Division. She has been an active member of AOAC for almost […]
analysis, analytics, AOAC, Business, Business Analysis, cannabis, CASP, compliance, develop, development, Dr, Dr. Katerina Mastovska, government, Growing, industry, International, Katerina, lab, laboratories, laboratory, legalization, Legalize, marijuana, Mastovska, method, Recreational, regulation, regulatory, safety, SMPR, standard, Standardization
December 20, 2022 blogger analysis, analytics, Business, Business Analysis, cannabis, CANNAFlix, compliance, Conference, consumer, event, government, Growing, industry, lab, laboratories, Laboratories & Analytics, laboratory, labs, Law, Legal, legalization, Legalize, legislation, license, marijuana, market, Medical, Medicial Marijuana, Medicine, Operations, Pesticide, product, Product Development, quality, RC - Cannabis & Hemp Testing Solutions, RC - Cannabis Analysis, RC - Cannabis Testing Accreditation Center, Recreational, regulation, Regulations, regulatory, Retail, safety, state, Stop Smoking Marijuana, Stop Smoking Pot, test, Testing, THC, virtual, webinar, weed, withdrawal
2022 Cannabis Labs Virtual Conference: December Program Sponsored by Avivatech & Millipore Sigma Click here to watch the recording Agenda Potency Inflation: The Problem, the Causes and the Solutions Sarah Otis, Quality, R&D Manager, Anresco Laboratories Erik Paulson, Ph.D., Lab Manager, InfiniteCAL THC potency inflation by third-party testing labs has been an escalating feature of […]
analysis, analytics, Business, Business Analysis, cannabis, CANNAFlix, compliance, Conference, consumer, event, government, Growing, industry, lab, laboratories, Laboratories & Analytics, laboratory, labs, Law, legal, legalization, Legalize, legislation, license, marijuana, market, Medical, Medicine, Operations, Pesticide, product, Product Development, quality, RC - Cannabis & Hemp Testing Solutions, RC - Cannabis Analysis, RC - Cannabis Testing Accreditation Center, Recreational, regulation, Regulations, regulatory, Retail, safety, state, test, Testing, THC, virtual, webinar
December 13, 2022 blogger AEssenseGrows, analysis, analytics, aroma, bud, Business, Business Analysis, cannabis, clone, color, compliance, consistency, Cultivate, Cultivation, Cultivation & Growing, cultivator, Culture, disease, genetics, grower, Growing, hybrid, industry, lab, laboratories, laboratory, legalization, Legalize, license, marijuana, market, Medicial Marijuana, Operations, plant size, product, profiles, quality, Recreational, Regulations, regulatory, resistance, safety, seed, size, state, Stop Smoking Marijuana, Stop Smoking Pot, Strain, Terpene, test, tested, Testing, THC, tissue, tolerance, weed, withdrawal, yield
This is Part 5 in The 3-Legged Stool of Successful Grow Operations series. Click here to see Part 1, here to see Part 2, here to see Part 3, and here to see part 4. Stay tuned for the final piece in the series, Part 6, coming in the new year. Genetics With climate and cultivation methods explored, today, […]
AEssenseGrows, analysis, analytics, aroma, bud, Business, Business Analysis, cannabis, clone, color, compliance, consistency, Cultivate, Cultivation, Cultivation & Growing, cultivator, Culture, disease, genetics, grower, Growing, hybrid, industry, lab, laboratories, laboratory, legalization, Legalize, license, marijuana, market, Operations, plant size, product, profiles, quality, Recreational, Regulations, regulatory, resistance, safety, seed, size, state, Strain, Terpene, test, tested, Testing, THC, tissue, tolerance, yield
December 9, 2022 blogger Affinity, analysis, analytics, bio, Business, Business Analysis, cannabinoid, cannabis, Christina Diarcangelo, clinical, diabetic, drug, Federal, government, Growing, head, industry, lab, laboratories, laboratory, labs, Law, Legal, legalization, Legalize, legislation, license, marijuana, Medical, Medicial Marijuana, Medicine, nerve, pain, Partners, pharma, pharmaceutical, product, Product Development, quality, regulation, regulatory, safety, state, Stop Smoking Marijuana, Stop Smoking Pot, Studies, Study, test, Testing, therapeutics, to, trial, weed, withdrawal, Zelira
Affinity Bio Partners on Working with Zelira Therapeutics to Complete Enrolment for Diabetic Nerve Pain Drug Trial It’s an exciting time in the medical cannabis community as Zelira, a global leader in the research, development and commercialization of clinically validated cannabinoid medicines, and Affinity Bio Partners, a leading, global clinical research organization, have completed enrollment […]
Affinity, analysis, analytics, bio, Business, Business Analysis, cannabinoid, cannabis, Christina Diarcangelo, clinical, diabetic, drug, Federal, government, Growing, head, industry, lab, laboratories, laboratory, labs, Law, legal, legalization, Legalize, legislation, license, marijuana, Medical, Medicine, nerve, pain, Partners, pharma, pharmaceutical, product, Product Development, quality, regulation, regulatory, safety, state, Studies, Study, test, Testing, therapeutics, to, trial, Zelira
November 30, 2022 blogger analysis, analytics, Business, Business Analysis, cannabis, compliance, consumer, Cultivation, Federal, government, Growing, industry, insurance, insure, laboratories, Law, Legal, legalization, Legalize, legislation, license, maage, management, marijuana, market, Medical, Medicial Marijuana, Medicine, Operations, product, quality, Recreational, regulation, Regulations, regulatory, Retail, risk, risks, safety, state, Stop Smoking Marijuana, Stop Smoking Pot, strategy, test, Testing, THC, weed, withdrawal
With an adverse regulatory environment, labor shortages, supply chain disruptions and the always-present threat of property damage and product recalls, cannabis operators are fighting an uphill battle to stay viable in today’s environment. According to Politico, more than 20 of the largest publicly-traded cannabis companies lost about $550 million on revenues of nearly $4.5 billion in […]
analysis, analytics, Business, Business Analysis, cannabis, compliance, consumer, Cultivation, Federal, government, Growing, industry, insurance, insure, laboratories, Law, legal, legalization, Legalize, legislation, license, maage, management, marijuana, market, Medical, Medicine, Operations, product, quality, Recreational, regulation, Regulations, regulatory, Retail, risk, risks, safety, state, strategy, test, Testing, THC
November 29, 2022 blogger analysis, analytics, Business, Business Analysis, California, cannabis, CANNAFlix, CBD, chain, compliance, Concentrates & Extracts, Conference, consumer, Cultivation, Cultivation & Growing, Dispensaries & Retail, dispensary, Edibles & Processing, event, extraction, Federal, government, Growing, industry, laboratories, Laboratories & Analytics, laboratory, Law, Legal, legalization, Legalize, legislation, license, marijuana, market, Medical, Medicial Marijuana, Operations, product, Product Development, quality, Recreational, regulation, Regulations, regulatory, Retail, state, Stop Smoking Marijuana, Stop Smoking Pot, supply, sustainability, virtual, webinar, weed, withdrawal
2022 Cannabis Supply Chain Virtual Conference Sponsored by CannaSpyGlass View On-Demand Now Click here to see all available CIJ events and webinars Agenda A Smarter Cannabis Beverage Distribution Model Jason Vegotsky, Chief Executive Officer, Petalfast Current cannabis distribution models make it hard for emerging cannabis beverage brands to launch and scale their businesses successfully. Instead, […]
analysis, analytics, Business, Business Analysis, California, cannabis, CANNAFlix, CBD, chain, compliance, Concentrates & Extracts, Conference, consumer, Cultivation, Cultivation & Growing, Dispensaries & Retail, dispensary, Edibles & Processing, event, extraction, Federal, government, Growing, industry, laboratories, Laboratories & Analytics, laboratory, Law, legal, legalization, Legalize, legislation, license, marijuana, market, Medical, Operations, product, Product Development, quality, Recreational, regulation, Regulations, regulatory, Retail, state, supply, sustainability, virtual, webinar
November 4, 2011 blogger cannabidiol, caregivers, CBD, dispensaries, green crack, hybrid, indica, lab testing, laboratories, marijuana, medical marijuana industry, Medicial Marijuana, News & Articles, northern lights, purple urkle, Romeo and Juliet, sativa, Stop Smoking Marijuana, Stop Smoking Pot, THC, William Shakespeare,
“What’s in a name? That which we call a rose
By any other name would smell as sweet.”
-William Shakespeare, Romeo and Juliet, Act 2-Scene 2 (The famous balcony Scene)
As Juliet so poetically stated, what truly is in a name? What lies under the surface is infinitely more important and while name games can be fun for some, they may not be for serious medical marijuana patients.
The safety of the medical marijuana industry needs to be an important concern. When someone is seeking relief from MS symptoms or other ailments, what are they to make of strain names such as “purple urkle” or “green crack”. The famous “Northern Lights” alone has many different variations and dispensaries are not always clear about which one they are selling or including in their hybrid strains. Another large problem is that many hybrid strains can be considered an Indica or a Sativa. While to some this is unimportant, there is a clear cut difference between the two. If one is seeking to alleviate insomnia but instead is given a strain that increases cerebral activity and paranoia, their experience may be less than enjoyable.
The need for a consistent industry is clear. Many of these concerns can be neutralized with lab testing. Imagine going to buy Tylenol and not knowing if it will be the same formula as the last time you purchased it for a headache. FDA regulations and the multi phased clinical trial model help to greatly increase consistency. Being close or pretty sure of a strains genetic makeup simply is not good enough. A brother and sister could have over 99% of the same genetics, but are they the same? Will they react to stimuli in identical fashion? Additionally, many medical marijuana users are concerned specifically with the chemical makeup of a particular strain. Cannabidiol (CBD) is a major component of marijuana and has been known to deliver more treatment and relief for medical issues. While a high level of THC is important for some, patients have other concerns and need to rely on lab testing in order to ensure that their medication is addressing their situation.
Much of this responsibility will have to fall on the collectives/caregivers for now. In order to serve their patients properly there needs to be a demand for medications to be tested on-site or in laboratories. In addition to a complete chemical breakdown, labs can also test for mold, insecticides, and other harmful hazards that can potentially be a part of the cultivation process. Juliet was correct in identifying that there is not much in a name, but ultimately we need to prove her wrong.
cannabidiol, caregivers, CBD, dispensaries, green crack, hybrid, indica, lab testing, laboratories, marijuana, medical marijuana industry, News & Articles, northern lights, purple urkle, Romeo and Juliet, sativa, THC, William Shakespeare